- In August 2026, Rhythm Pharmaceuticals reported second-quarter 2026 results showing revenue of US$71.26 million versus US$48.50 million a year earlier, alongside a net loss of US$49.30 million and slightly improved loss per share.
- The company also released early Phase 2 data for its weekly MC4R agonist RM-718 in acquired hypothalamic obesity, showing double-digit BMI reductions with fewer pigmentation issues, highlighting progress beyond its first-generation IMCIVREE franchise.
- Now we’ll assess how stronger IMCIVREE revenues and promising RM-718 data may refine Rhythm’s existing investment narrative around growth and risk.
Uncover the next big thing with 19 elite penny stocks that balance risk and reward
Advertisement
Rhythm Pharmaceuticals Investment Narrative Recap
To own Rhythm Pharmaceuticals, you need to believe IMCIVREE can build a durable rare‑disease franchise while next‑generation MC4R assets like RM‑718 broaden the opportunity set, all while the company works through sizeable losses. The latest quarter confirms stronger IMCIVREE revenues but also ongoing net losses, so the most important near term catalyst remains continued commercial uptake in acquired hypothalamic obesity, while the biggest risk is Rhythm’s need to fund a still loss‑making, R&D‑heavy business.
The preliminary Phase 2 data for RM‑718 in acquired hypothalamic obesity looks most relevant here, as it reinforces Rhythm’s push beyond its first generation setmelanotide franchise with a once weekly, MC4R specific agent that appears to reduce BMI and limit generalized hyperpigmentation. How effectively Rhythm can convert this early clinical signal into a broader MC4R pathway pipeline will intersect directly with future capital needs and the company’s ability to narrow its net losses
Yet behind the stronger IMCIVREE sales and encouraging RM‑718 data, investors still need to be aware that
Read the full narrative on Rhythm Pharmaceuticals (it’s free!)
Rhythm Pharmaceuticals’ narrative projects $971.3 million revenue and $263.4 million earnings by 2029. This requires 64.8% yearly revenue growth and a $471.2 million earnings increase from -$207.8 million today
Uncover how Rhythm Pharmaceuticals’ forecasts yield a $139.47 fair value, a 26% upside to its current price
Exploring Other Perspectives
Two fair value estimates from the Simply Wall St Community span roughly US$139 to US$520 per share, highlighting very different expectations. When you set these side by side with Rhythm’s continued operating losses despite higher IMCIVREE revenue, it underlines why examining multiple viewpoints on the company’s risk and reward profile can be so important
Explore 2 other fair value estimates on Rhythm Pharmaceuticals – why the stock might be worth over 4x more than the current price!
Form Your Own Verdict
Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own
- A great starting point for your Rhythm Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
- Our free Rhythm Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Rhythm Pharmaceuticals’ overall financial health at a glance.
Seeking Other Investments?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- We’ve uncovered the 8 dividend fortresses yielding 5%+ that don’t just survive market storms, but thrive in them.
- This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New:AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities
• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics
Explore Now for Free
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
About NasdaqGM:RYTM
Rhythm Pharmaceuticals
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally
See The Free Research Report
High growth potential with adequate balance sheet
See The Free Research Report
Similar Companies
Neuren Pharmaceuticals
CNSX:DRUG
Bright Minds Biosciences
Market Insights
What does frontier-beating open source mean for AI investors?Andrew Legget
Why 2026’s worst-looking sector might be its most misreadMitchell Lawler
A brand’s strength doesn’t always lastRichard Bowman
Advertisement
Weekly Picks
CE
Ceazaron Sparc AI·4 months ago
When GPS fails: this small cap is fixing a $54B drone problem
Fair Value:CA$5.2535.8% undervalued
146followersusers have followed this narrative
·0commentsusers have commented on this narrative
·26likesusers have liked this narrative
HA
HarishPKon Amdocs·about 1 month ago
Why Amdocs is a high conviction Buy for me?
Fair Value:US$82.0332.6% undervalued
31followersusers have followed this narrative
·3commentsusers have commented on this narrative
·10likesusers have liked this narrative
IV
Ivoedon SBM Offshore·about 1 month ago
Why SBM Offshore’s €30 Share Price May Be Too Harsh On Its Backlog
Fair Value:€44.521.1% undervalued
15followersusers have followed this narrative
·0commentsusers have commented on this narrative
·4likesusers have liked this narrative
CL
Clive_Thompsonon Green Tea Group·10 days ago
One of China’s Fastest-Growing Restaurant Chains Trades on Just 7x Earnings and an 8% Dividend
Fair Value:HK$8.726.3% undervalued
41followersusers have followed this narrative
·3commentsusers have commented on this narrative
·18likesusers have liked this narrative
RecentlyUpdated Narratives
HU
Hunter_Zon Oriental Kopi Holdings Berhad·about 10 hours ago
Oriental Kopi’s Indonesia JV Strengthens Regional Growth Narrative
Fair Value:RM 1.533.7% undervalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
ST
StoxEuropeon UCB·about 10 hours ago
FV 206,24 but with a 310-154 range…to discuss
Fair Value:€206.249.1% overvalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
TI
TickerTickleon Figma·about 18 hours ago
Figma (FIG): The S&P 500’s Design Standard Turning Into an All-in-One Platform
Fair Value:US$22.3625.9% overvalued
62followersusers have followed this narrative
·7commentsusers have commented on this narrative
·0likesusers have liked this narrative
Popular Narratives
OS
oscargarciaon NVIDIA·2 months ago
The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century
Fair Value:US$28021.7% undervalued
260followersusers have followed this narrative
·9commentsusers have commented on this narrative
·16likesusers have liked this narrative
CU
CubanEroson Microsoft·about 1 month ago
A wonderful business at reasonable price
Fair Value:US$419.9116.1% overvalued
128followersusers have followed this narrative
·0commentsusers have commented on this narrative
·7likesusers have liked this narrative
TR
tripledubon Alphabet·4 days ago
Warren Buffett Just Bet $10 Billion on Google. The Catch? You May Already Be Too Late
Fair Value:US$202.6278.9% overvalued
139followersusers have followed this narrative
·1commentusers have commented on this narrative
·18likesusers have liked this narrative
